The study’s findings suggest that greater than 90% of Japanese patients develop complications from ILD (of which approximately 80% of patients develop the rapidly progressive subtype), whereas only 50% of American patients with anti-MDA5 develop ILD, with fewer patients developing RP-ILD (49). This evidence concerns the gene IFIH1 and interstitial lung disease.